{"id":390890,"date":"2017-10-05T00:00:00","date_gmt":"2017-10-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0013-2017-biopharma-parkinsons-disease-unmet-need-adjunctive-therapies-for-motor-response-fluctuations-us-eu\/"},"modified":"2026-04-22T05:25:59","modified_gmt":"2026-04-22T05:25:59","slug":"unnecg0013-2017-biopharma-parkinsons-disease-unmet-need-adjunctive-therapies-for-motor-response-fluctuations-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0013-2017-biopharma-parkinsons-disease-unmet-need-adjunctive-therapies-for-motor-response-fluctuations-us-eu\/","title":{"rendered":"Parkinson&#8217;s Disease | Unmet Need | Adjunctive Therapies for Motor Response Fluctuations | US\/EU | 2017"},"content":{"rendered":"<p>Although motor fluctuations in Parkinson\u2019s disease (PD) can be managed effectively in the early stages of the disease, today\u2019s treatment paradigm is suboptimal owing to the considerable pill burden, a risk of motor and nonmotor complications associated with dopaminergic therapy, and a progressive loss of efficacy. In response, the pipeline for adjunctive therapies targeting motor fluctuations has swelled. With the recent launches of Xadago and Ongentys\u00a0and with Nouriast and tozadenant in late-phase development, understanding the drivers of clinical decision-making for treating motor fluctuations and prescriber perceptions of approved options will help innovators identify levers for new product positioning and differentiation in this evolving market niche.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for motor fluctuations in PD?<\/li>\n<li>What attributes are key influences, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for motor fluctuations in PD?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in the treatment of\u00a0motor fluctuations in PD?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new adjunctive drug for the treatment of motor fluctuations in PD?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 31 European neurologists fielded in February 2017<\/p>\n<p><strong>Key companies:<\/strong> Teva, UCB, Newron, Zambon, US WorldMeds, Bial, Neurocrine, Kyowa Hakko Kirin, Acorda<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0oral dopamine agonists, rotigotine (Neupro), rasagiline (Azilect), selegiline, safinamide (Xadago), entacapone, Ongentys (opicapone), tozadenant, Nouriast (istradefylline)<\/p>\n","protected":false},"template":"","class_list":["post-390890","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-parkinsons-disease","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390890\/revisions"}],"predecessor-version":[{"id":394014,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390890\/revisions\/394014"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}